I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Kipps, T. J.
141
results:
Search for persons
X
Format
Online (141)
Mediatypes
Articles (Online) (69)
Bookchapter (Online) (1)
OpenAccess-fulltext (71)
Sorted by: Relevance
Sorted by: Year
?
1
Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cel..:
Lee, H.
;
Choi, M.
;
Siddiqi, T.
...
Hematological Oncology. 41 (2023) S2 - p. 587-589 , 2023
Link:
https://doi.org/10.1002/..
?
2
MURANO: Final 7 year follow up and retreatment analysis in ..:
Kater, A. P.
;
Harrup, R.
;
Kipps, T. J.
...
Hematological Oncology. 41 (2023) S2 - p. 239-242 , 2023
Link:
https://doi.org/10.1002/..
?
3
P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-..:
Moreno, C.
;
Wierda, W. G.
;
Barr, P. M.
...
HemaSphere. 6 (2022) - p. 567-568 , 2022
Link:
https://doi.org/10.1097/..
?
4
FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRON..:
Coutre, S. E.
;
Barr, P. M.
;
Owen, C.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
5
UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITU..:
Wu, J. Q.
;
Seymour, J. F.
;
Eichhorst, B.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
6
CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIX..:
Tam, C. S. L
;
Allan, J. N
;
Siddiqi, T
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
7
FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AN..:
Fischer, K.
;
Porro Lurà, M.
;
Al‐Sawaf, O.
...
Hematological Oncology. 37 (2019) S2 - p. 82-84 , 2019
Link:
https://doi.org/10.1002/..
?
8
IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/..:
Wu, J.
;
Bolen, C.
;
Seymour, J.F.
...
Hematological Oncology. 37 (2019) S2 - p. 106-108 , 2019
Link:
https://doi.org/10.1002/..
?
9
PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB‐INTOLERANT PATI..:
Rogers, K.A.
;
Thompson, P.A.
;
Allan, J.N.
...
Hematological Oncology. 37 (2019) S2 - p. 60-61 , 2019
Link:
https://doi.org/10.1002/..
?
10
FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT O..:
Tedeschi, A.
;
Burger, J.
;
Barr, P.M.
...
Hematological Oncology. 37 (2019) S2 - p. 103-104 , 2019
Link:
https://doi.org/10.1002/..
?
11
Leukemia-cell proliferation and disease progression in pati..:
Murphy, E J
;
Neuberg, D S
;
Rassenti, L Z
...
Leukemia. 31 (2017) 6 - p. 1348-1354 , 2017
Link:
https://doi.org/10.1038/..
?
12
Extended follow-up and impact of high-risk prognostic facto..:
Brown, J R
;
Hillmen, P
;
O'Brien, S
...
Leukemia. 32 (2017) 1 - p. 83-91 , 2017
Link:
https://doi.org/10.1038/..
?
13
LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTI..:
Montillo, M.
;
Byrd, J.C.
;
Hillmen, P.
...
Hematological Oncology. 35 (2017) S2 - p. 235-236 , 2017
Link:
https://doi.org/10.1002/..
?
14
INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS..:
Kipps, T.J.
;
Fraser, G.
;
Coutre, S.E.
...
Hematological Oncology. 35 (2017) S2 - p. 109-111 , 2017
Link:
https://doi.org/10.1002/..
?
15
Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced c..:
Yu, J
;
Chen, L
;
Chen, Y
...
Leukemia. 31 (2017) 12 - p. 2608-2614 , 2017
Link:
https://doi.org/10.1038/..
1-15